Global Diabetes Trends and Treatment Gaps: 1990-2022 Analysis

By Rene Pretorius

November 27, 2024

What are the global trends in diabetes prevalence and treatment over the past three decades, and how do they compare across countries? A study published in The Lancet examines global diabetes trends from 1990 to 2022. This research highlights the alarming rise in diabetes prevalence and treatment gaps, emphasizing the urgent need for action.

Global Prevalence of Diabetes

The global rate of diabetes (combining type 1 and type 2) in adults has doubled from approximately 7% in 1990 to about 14% in 2022.
This increase has resulted in over 800 million adults living with diabetes worldwide, which is more than four times the number in 1990.

Regional Variations in Diabetes Prevalence and Treatment

The largest increases in diabetes rates were observed in low- and middle-income countries (LMICs), where the disease burden has significantly risen. In contrast, regions like North America, Australasia, central and western Europe, and parts of Latin America and East Asia and the Pacific have seen improvements in diabetes treatment rates, contributing to widening global inequities in diabetes treatment.

Global Diabetes Treatment Gaps

Despite the increasing prevalence, treatment rates for diabetes have stagnated at low levels in many LMICs. As a result, nearly 450 million adults aged 30 and over with diabetes (approximately 59%) did not receive treatment in 2022.

Policy Implications

The findings emphasize the urgent need for financing of medicines and comprehensive diabetes programs to enable early detection and effective treatment of diabetes, particularly in LMICs. Overall, the study underscores the growing global burden of diabetes, especially in low-income regions, and highlights the critical need for improved access to diabetes treatment and care.

Reference url

Recent Posts

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

donanemab Alzheimer’s treatment cost-effectiveness
            

NICE Rejects Donanemab: Treatment Cost-Effectiveness

💡 How cost-effective is the new Alzheimer’s treatment, donanemab?

NICE’s latest guidance reveals that while donanemab shows some promise in slowing cognitive decline, its high costs and limited clinical benefits have led to its rejection for routine NHS use. This decision highlights the significant challenges in balancing innovation with economic sustainability in healthcare.

Dive into the full analysis to understand the implications for future Alzheimer’s therapies and the rigorous standards shaping NHS adoption.

#SyenzaNews #HealthEconomics #HealthcarePolicy

Ultomiris pediatric TMA treatment
      

Efficacy of Ultomiris Pediatric TMA Treatment

🌟 Wondering how new treatments are changing the landscape for pediatric patients with TMA?

Recent findings from the Phase III trial of Ultomiris show an impressive 87% overall survival rate at 26 weeks for children suffering from thrombotic microangiopathy following stem cell transplantation. With a promising safety profile and significant clinical improvements, this could be a game changer for an ultra-rare disease lacking effective therapies.

Curious about the implications of these results on healthcare outcomes and market access? Dive into the article for an in-depth look!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.